Financials in USD. Standardized financial statements.
A compact view of how Sinovac Biotech Ltd. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $448.27M | $1.49B | $19.37B | $510.62M | $246.05M | $229.65M | $174.35M | $72.43M | $67.41M | $62.93M |
| Revenue Growth? | -70.0% | -92.3% | +3694.4% | +107.5% | +7.1% | +31.7% | +140.7% | +7.4% | +7.1% | 0.0% |
| Cost of Revenue? | $181.52M | $684.46M | $1.07B | $67.18M | $32.47M | $24.72M | $20.24M | $22.39M | $18.41M | $15.48M |
| Gross Profit? | $266.75M | $808.30M | $18.30B | $443.44M | $213.58M | $204.93M | $154.11M | $50.04M | $49.01M | $47.46M |
| Gross Margin? | +59.5% | +54.1% | +94.5% | +86.8% | +86.8% | +89.2% | +88.4% | +69.1% | +72.7% | +75.4% |
| Operating Expenses? | $813.48M | $1.27B | $748.45M | $227.64M | $144.73M | $159.54M | $108.65M | $49.06M | $45.28M | $45.50M |
| Operating Income? | -$546.72M | -$466.07M | $17.55B | $215.64M | $68.56M | $45.32M | $45.42M | $504,000 | $3.69M | $1.89M |
| EBITDA? | -$6.03M | $183.10M | $17.65B | $221.76M | $76.05M | $52.54M | $51.25M | $6.64M | $10.93M | $13.86M |
| Income Before Tax | -$153.03M | $25.24M | $17.56B | $216.62M | $70.82M | $46.58M | $45.04M | -$394,000 | $2.76M | $2.35M |
| Income Tax Expense | $105.32M | -$62.89M | $3.10B | $31.44M | $5.61M | $10.47M | $8.34M | $2.66M | $2.98M | $2.07M |
| Net Income? | -$99.92M | $113.87M | $8.47B | $110.37M | $44.93M | $21.78M | $25.81M | -$596,000 | -$1.42M | -$1.51M |
| EPS? | $-1.06 | $1.08 | $85.20 | $1.06 | $0.42 | $0.34 | $0.45 | $-0.01 | $-0.03 | $-0.03 |
| Diluted EPS? | $-1.06 | $1.00 | $74.27 | $0.97 | $0.41 | $0.34 | $0.45 | $-0.01 | $-0.03 | $-0.03 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality